Copyright © 2013 American Medical Association. All rights reserved. From: Oral Antimycobacterial Therapy in Chronic Cutaneous SarcoidosisA Randomized, Single-Masked, Placebo-Controlled Study JAMA Dermatol. 2013;149(9):1040-1049. doi:10.1001/jamadermatol.2013.4646 Figure Legend: Cutaneous Sarcoidosis Trial Flow DiagramRecruitment and enrollment of patients with chronic cutaneous sarcoidosis. Date of download: 12/18/2017 Copyright © 2013 American Medical Association. All rights reserved.

Copyright © 2013 American Medical Association. All rights reserved. From: Oral Antimycobacterial Therapy in Chronic Cutaneous SarcoidosisA Randomized, Single-Masked, Placebo-Controlled Study JAMA Dermatol. 2013;149(9):1040-1049. doi:10.1001/jamadermatol.2013.4646 Figure Legend: Change in Lesion Diameter and Sarcoidosis Activity Severity Index (SASI) From Baseline to 8 WeeksA, Change in lesion diameter was apparent in those randomized to the concomitant levofloxacin, ethambutol, azithromycin, and rifampin (CLEAR) regimen compared with the cohort taking placebo, with complete resolution of the cutaneous lesions among 5 patients in the CLEAR group. B, A significant decline in the SASI was observed in the CLEAR group; minimal change was observed in the placebo group. Each colored bar represents an individual study participant. Date of download: 12/18/2017 Copyright © 2013 American Medical Association. All rights reserved.

Copyright © 2013 American Medical Association. All rights reserved. From: Oral Antimycobacterial Therapy in Chronic Cutaneous SarcoidosisA Randomized, Single-Masked, Placebo-Controlled Study JAMA Dermatol. 2013;149(9):1040-1049. doi:10.1001/jamadermatol.2013.4646 Figure Legend: Photographs of Observed Clinical Improvement of Ulcerative SarcoidosisPhotographic depictions of ulcerative sarcoidosis at baseline (A) and following completion of the concomitant levofloxacin, ethambutol, azithromycin, and rifampin (CLEAR) regimen (B). Date of download: 12/18/2017 Copyright © 2013 American Medical Association. All rights reserved.

Copyright © 2013 American Medical Association. All rights reserved. From: Oral Antimycobacterial Therapy in Chronic Cutaneous SarcoidosisA Randomized, Single-Masked, Placebo-Controlled Study JAMA Dermatol. 2013;149(9):1040-1049. doi:10.1001/jamadermatol.2013.4646 Figure Legend: Gene Expression Profile Changes Following Concomitant Levofloxacin, Ethambutol, Azithromycin, and Rifampin (CLEAR) TreatmentThe heat maps represent statistically significant (P < .05), differentially expressed genes in CD4+ (A) and CD8+ (B) sorted cells, respectively. Upregulated genes are shown in progressively brighter shades of yellow, depending on the fold difference, and downregulated genes are shown in progressively brighter shades of purple. Gray, expression of genes that show no difference between the 2 groups being compared. The functional enrichment of these differentially expressed genes in CD4+ (C) and CD8+ (D) sorted cells is shown. Post indicates postintervention; pre, preintervention. Date of download: 12/18/2017 Copyright © 2013 American Medical Association. All rights reserved.

Copyright © 2013 American Medical Association. All rights reserved. From: Oral Antimycobacterial Therapy in Chronic Cutaneous SarcoidosisA Randomized, Single-Masked, Placebo-Controlled Study JAMA Dermatol. 2013;149(9):1040-1049. doi:10.1001/jamadermatol.2013.4646 Figure Legend: T-Cell Function Improvement With Concomitant Levofloxacin, Ethambutol, Azithromycin, and Rifampin (CLEAR) TherapyCD4+ T cells were stimulated with anti-CD3/anti-CD28 antibodies. A, Supernatants were collected at 24 hours and measured for fold change in interleukin 2 (IL-2) and interferon γ (IFN-γ) production by a cytokine bead array in patients receiving CLEAR therapy. B, Representative change in percentage of CD4+ T-cell proliferation from baseline to 8 weeks among patients randomized to the CLEAR- and placebo-treated groups. CD4+ T cells were labeled with carboxyfluorescein succinimidyl ester and stimulated with anti-CD3/anti-CD28 antibodies. Cells were collected after 5 days, and proliferation was measured by flow cytometry. C, Cumulative proliferation data. Specimens were chosen solely based on availability of peripheral blood mononuclear cells. Data represent the mean (horizontal bars) percentage from 9 patients in the CLEAR-treated group and 4 placebo-treated patients. CFSE indicates carboxyfluorescein succinimidyl ester. Date of download: 12/18/2017 Copyright © 2013 American Medical Association. All rights reserved.